Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Truemper · SciRah

Researcher profile · Semantic Scholar

L. Truemper

Share profile

L. Truemper — researcher profile on SciRah

h-index: 27
Works: 154
Citations: 3,374

Most-cited papers

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
N. Schmitz, M. Nickelsen, M. Ziepert, M. Haenel +13 more
2012The Lancet Oncology234 citations
Semantic Scholar
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
V. Poeschel, G. Held, M. Ziepert, M. Witzens-Harig +40 more
2019The Lancet208 citations Open access
Semantic Scholar
Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration
B. Chapuy, R. Koch, U. Radunski, S. Corsham +11 more
2008Leukemia155 citations Open access
Semantic Scholar
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
N. Schmitz, S. Zeynalova, B. Glass, U. Kaiser +6 more
2012Annals of Oncology114 citations Open access
Semantic Scholar
Nuclear Trapping through Inhibition of Exosomal Export by Indomethacin Increases Cytostatic Efficacy of Doxorubicin and Pixantrone
R. Koch, T. Aung, D. Vogel, B. Chapuy +8 more
2015Clinical Cancer Research108 citations Open access
Semantic Scholar
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.
B. Glass, J. Hasenkamp, G. Wulf, P. Dreger +10 more
2014The Lancet Oncology104 citations
Semantic Scholar
Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
M. Pfreundschuh, V. Poeschel, S. Zeynalova, M. Hänel +13 more
2014Journal of Clinical Oncology87 citations Open access
Semantic Scholar
ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug
B. Chapuy, Melanie Panse, U. Radunski, R. Koch +5 more
2009Haematologica87 citations Open access
Semantic Scholar
Microarray‐based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status
C. Schwaenen, A. Viardot, H. Berger, Thomas F. E. Barth +24 more
2009Genes, Chromosomes and Cancer76 citations
Semantic Scholar
Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients
M. Pfreundschuh, N. Murawski, S. Zeynalova, M. Ziepert +15 more
2017British Journal of Haematology53 citations Open access
Semantic Scholar
Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL.
M. Pfreundschuh, M. Ziepert, S. Zeynalova, E. Lengfelder +12 more
2011Journal of Clinical Oncology51 citations
Semantic Scholar
Pathway activation patterns in diffuse large B-cell lymphomas
S. Bentink, S. Wessendorf, C. Schwaenen, M. Rosolowski +17 more
2008Leukemia50 citations
Semantic Scholar
Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL/GLA.
M. Pfreundschuh, N. Murawski, M. Ziepert, B. Altmann +15 more
201843 citations
Semantic Scholar
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance
T. Hupfeld, B. Chapuy, Verena Schrader, Markus Beutler +8 more
2013British Journal of Haematology43 citations Open access
Semantic Scholar
Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.
E. Hoster, B. Metzner, R. Forstpointner, M. Pfreundschuh +10 more
200943 citations
Semantic Scholar
Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
A. Zoellner, M. Unterhalt, S. Stilgenbauer, K. Hübel +18 more
2021The Lancet Haematology37 citations Open access
Semantic Scholar
Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.
N. Schmitz, M. Nickelsen, B. Altmann, M. Ziepert +15 more
201734 citations
Semantic Scholar
Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant
F. d'Amore, S. Leppä, M. D. da Silva, T. Relander +54 more
2018Blood30 citations Open access
Semantic Scholar
Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: Results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL.
M. Pfreundschuh, Konstantinos Christofyllakis, B. Altmann, M. Ziepert +16 more
201730 citations
Semantic Scholar
CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial
C. Binder, M. Ziepert, M. Pfreundschuh, U. Duhrsen +6 more
2013Annals of Hematology30 citations Open access
Semantic Scholar
Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL).
Norbert Schmitz, M. Nickelsen, M. Ziepert, M. Haenel +11 more
2011Journal of Clinical Oncology30 citations
Semantic Scholar
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
F. Frontzek, M. Ziepert, M. Nickelsen, B. Altmann +17 more
2021The Lancet Haematology24 citations
Semantic Scholar
Increased rituximab (R) doses and effect on risk of elderly male patients with aggressive CD20+ B-cell lymphomas: Results from the SEXIE-R-CHOP-14 trial of the DSHNHL.
M. Pfreundschuh, G. Held, S. Zeynalova, C. Zwick +7 more
201424 citations
Semantic Scholar
Intracellular ATP-Binding Cassette Transporter A3 is Expressed in Lung Cancer Cells and Modulates Susceptibility to Cisplatin and Paclitaxel
T. Overbeck, T. Hupfeld, Doris Krause, R. Waldmann-Beushausen +8 more
2013Oncology20 citations Open access
Semantic Scholar
Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma
M. Dreyling, E. Hoster, A. van Hoof, B. Metzner +11 more
200820 citations
Semantic Scholar
Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non‐Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation
B. Chapuy, N. Schuelper, Melanie Panse, A. Dohm +4 more
2011British Journal of Haematology19 citations Open access
Semantic Scholar
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant
K. Savage, S. Horwitz, R. Advani, J. Christensen +19 more
2019Blood17 citations Open access
Semantic Scholar
Excellent Outcome of Young Patients (18-60 years) with Favourable-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 4 Cycles CHOP Plus 6 Applications of Rituximab: Results of the 592 Patients of the Flyer Trial of the Dshnhl/GLA
V. Poeschel, G. Held, M. Ziepert, B. Altmann +21 more
2018Blood17 citations
Semantic Scholar
Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials
B. Altmann, G. Wulf, L. Truemper, F. d'Amore +6 more
2018Blood16 citations Open access
Semantic Scholar
Rituximab for Graft-Versus-Host-Disease-Prophylaxis after Allogeneic Stem Cell Transplantation Given as Treatment of High Risk Relapse of Aggressive Lymphoma: Results of a Randomized Phase II Study.
B. Glass, J. Hasenkamp, Anke Görlitz, P. Dreger +5 more
200816 citations
Semantic Scholar
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
L. Thurner, M. Ziepert, C. Berdel, C. Schmidt +43 more
2023HemaSphere15 citations Open access
Semantic Scholar
Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
K. Hohloch, M. Ziepert, L. Truemper, C. Buske +4 more
2020eJHaem15 citations Open access
Semantic Scholar
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
G. Held, L. Thurner, V. Poeschel, G. Ott +29 more
2023HemaSphere14 citations Open access
Semantic Scholar
The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
S. Horwitz, O. O'Connor, B. Pro, Tim M. Illidge +26 more
2020Blood14 citations Open access
Semantic Scholar
First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
F. d'Amore, S. Leppä, Maria Comes da Silva, T. Relander +42 more
201214 citations
Semantic Scholar
Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
S. Stilgenbauer, T. Zenz, D. Winkler, A. Bühler +13 more
200814 citations
Semantic Scholar
RADIOTHERAPY TO BULKY DISEASE PET‐NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF a PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL > 60 STUDY OF THE DSHNHL
M. Pfreundschuh, Konstantinos Christofyllakis, B. Altmann, M. Ziepert +17 more
201713 citations Open access
Semantic Scholar
Refractory or relapsed aggressive B-cell lymphoma failing (R)-CHOP: an analysis of patients treated on the RICOVER-60 trial
B. Glass, A. Dohm, L. Truemper, M. Pfreundschuh +5 more
2017Annals of Oncology13 citations Open access
Semantic Scholar
First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study.
Norbert Shmitz, L. Truemper, M. Ziepert, K. Bouabdallah +16 more
2019Journal of Clinical Oncology11 citations
Semantic Scholar
FIRST‐LINE THERAPY OF T‐CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION ‐ FINAL RESULTS OF THE AATT STUDY
O. Tournilhac, L. Truemper, M. Ziepert, K. Bouabdallah +25 more
2019Hematological Oncology9 citations
Semantic Scholar
Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network
Karin Hohloch, P. Zinzani, Werner Linkesch, Wojciech Jurczak +5 more
2011Bone Marrow Transplantation9 citations Open access
Semantic Scholar
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, Stuttgart, 29. September-3. Oktober 2017: Abstracts
N. Murawski, Josif Amam, B. Altmann, M. Ziepert +13 more
2017Oncology Research and Treatment8 citations Open access
Semantic Scholar
Retrospective web-based multicenter evaluation of 18F-FDG-PET and CT derived predictive factors
A. Grgic, U. Nestle, K. Scheidhauer, C. Puskás +8 more
2010Nuklearmedizin8 citations
Semantic Scholar
KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
D. Kaddu-Mulindwa, B. Altmann, S. Robrecht, M. Ziepert +18 more
2022The Lancet Haematology7 citations
Semantic Scholar
The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma
S. Horwitz, K. Savage, T. Illidge, S. Iyer +12 more
2021Blood6 citations Open access
Semantic Scholar
Progression of a CD4+/CD56+ blastic plasmacytoid DC neoplasm after initiation of extracorporeal photopheresis in an allogeneic transplant recipient
A. Dohm, J. Hasenkamp, H. Bertsch, J. Maas +2 more
2011Bone Marrow Transplantation6 citations
Semantic Scholar
A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial
J. Burke, M. André, B. Cheson, J. Duell +12 more
2019Blood5 citations Open access
Semantic Scholar
Granulocytic Sarcoma by AML M4eo (inv16) after Allogeneic Stem Cell Transplantation without Bone Marrow Involvement
S. Zaenker, S. Schweyer, J. Hasenkamp, L. Truemper +1 more
2011Case Reports in Hematology5 citations Open access
Semantic Scholar
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial
D. Kaddu-Mulindwa, V. Lesan, C. Berdel, S. Stilgenbauer +13 more
2021Leukemia and Lymphoma4 citations
Semantic Scholar
Allogeneic Stem Cell Transplantation with Intermediate Conditioning Is Effective in High Risk Relapse and Progressive Disease of Aggressive Non-Hodgkin-Lymphoma.
B. Glass, J. Hasenkamp, Anke Goerlitz, P. Dreger +5 more
20094 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Ziepert×23
Invite
M. Ziepert — researcher profile on SciRah
B. Altmann×17
Invite
B. Altmann — researcher profile on SciRah
N. Schmitz×16
Invite
N. Schmitz — researcher profile on SciRah
G. Wulf×16
Invite
G. Wulf — researcher profile on SciRah

×15

Invite

G. Held — researcher profile on SciRah

Invite

A. Viardot — researcher profile on SciRah

M. Pfreundschuh×12

Invite

M. Pfreundschuh — researcher profile on SciRah

Invite

B. Glass — researcher profile on SciRah

V. Poeschel×12

Invite

V. Poeschel — researcher profile on SciRah

M. Nickelsen×11

Invite

M. Nickelsen — researcher profile on SciRah

Invite

M. Haenel — researcher profile on SciRah

A. Rosenwald×11

Invite

A. Rosenwald — researcher profile on SciRah